Media Mention

Too early to conclude on Hong Kong's attractiveness as biotech IPO destination

Stephen Peepels spoke to the South China Morning Post on the attractiveness of Hong Kong as a biotech IPO destination under the new listing rules.

Published Works

The controversy over gene-editing

Press Releases

Hogan Lovells rings in the New Year with 30 promotions to partner and 47 promotions to counsel

LONDON and WASHINGTON, D.C., 3 January 2019 – Global law firm Hogan Lovells today announced that 30 of its people have been promoted to partner effective 1 January across its global...

Press Releases

Media briefing note Controversy over gene editing comment Hogan Lovells as Chinese research greeted with consternation

Shortly before the start of the second international summit on human genome editing in Hong Kong this week, it was announced that Chinese researcher, He Jiankui, had successfully used a...

Press Releases

Hogan Lovells advises Valneva in its €50 million fundraising

Hogan Lovells has advised Valneva in its €50 million fundraising of gross proceeds in a private placement of its ordinary shares.

Awards and Rankings

Hogan Lovells named LMG Life Science Regulatory Firm of the Year, Alice Valder Curran and Adam Golden named Regulatory and M&A Attorneys of the Year

Washington, D.C., 25 September 2018 – Hogan Lovells is pleased to announce that it scored three major wins at the sixth annual LMG Life Sciences Awards honoring top-ranking firms and...

Awards and Rankings

Hogan Lovells named Who's Who Legal Firm of the Year 2018

London, 11 May 2018 – Hogan Lovells has been recognised as the Who’s Who Legal Firm of the Year for 2018. Hogan Lovells received the award at a dinner in London on the evening...

Press Releases

Hogan Lovells Advises on Groundbreaking FDA Grant of De Novo Request to Market a Novel Artificial Intelligence-based Device

Philadelphia / San Francisco, 16 April 2018 – IDx LLC, with assistance from Hogan Lovells, achieved a major grant of De Novo classification from the U.S. Food and Drug Administration...

Loading data